This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff reported an open-market sale of 721 shares of Voting Common Stock on May 7, 2026 at a weighted average price of $28.28 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025, indicating it was scheduled in advance. After this transaction, Woodruff directly holds 242,729 shares of the company’s stock. The filing notes that the shares were sold in multiple trades at prices between $28.08 and $28.90 per share.
MapLight Therapeutics, Inc. Chief Financial Officer Vishwas Setia reported open-market sales of a total of 36,371 shares of Voting Common Stock over May 4–6, 2026. The trades were executed at weighted average prices reported between about $26.84 and $30.55 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025. Following these transactions, Setia directly owns 356,256 shares of MapLight Therapeutics common stock.
MapLight Therapeutics Chief Medical Officer Erin Pennock Foff sold 50,280 shares of Voting Common Stock in open-market trades. The sales occurred on May 4–6, 2026 at prices generally in the high‑$20s to low‑$30s per share.
The transactions were made under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled. After these sales, Foff directly holds 350,497 shares of MapLight Therapeutics common stock.
MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff sold 51,707 shares of Voting Common Stock in open‑market transactions. The sales occurred on May 4–6, 2026 at prices reported around the high‑$20s to low‑$30s per share, with some trades executed at weighted average prices.
After these transactions, Woodruff directly holds 243,450 shares of Voting Common Stock. The filing states that the trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled rather than discretionary market‑timed sales.
MapLight Therapeutics General Counsel Kristopher Hanson reported selling 13,917 shares of Voting Common Stock in open‑market trades. The sales occurred on May 4, 2026 at weighted average prices, with individual trades ranging from $26.84 to $30.55 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025. After the sales, Hanson directly holds 176,248 shares.
MapLight Therapeutics, Inc. director and CEO Christopher A. Kroeger reported open‑market sales of Voting Common Stock. Over May 4–6, 2026, he sold a total of 49,744 shares in multiple transactions classified as open‑market sales under code S, at prices reported as weighted averages.
The filing shows these transactions were executed pursuant to a Rule 10b5‑1 trading plan adopted on December 29, 2025, meaning they were pre‑scheduled. After the reported sales, Kroeger directly holds 1,580,820 shares of Voting Common Stock and an additional 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse have voting and dispositive power.
MapLight Therapeutics, Inc. (MPLT) officer Christopher A. Kroeger filed notice of a proposed sale of 236,470 common shares, with an approximate sale date of May 4, 2026 and aggregate market value of $7,259,629.00.
The shares were acquired upon vesting of restricted stock units from July 5, 2024 through April 1, 2026. Sales are to be made pursuant to a previously signed/adopted Rule 10b5-1 selling plan dated December 29, 2025.
The notice also lists sales of 9,135 shares for gross proceeds of $246,020.99 on April 15, 2026, and 10,052 shares for gross proceeds of $275,140.33 on April 16, 2026.
Maplight Therapeutics notified a proposed sale of 36,371 shares of Common Stock, described on the form with an aggregate value of $1,116,589.70. The sale is tied to vested RSUs and listed with Jefferies LLC as the broker on 05/04/2026.
The filing also records recent dispositions by Vishwas Setia of 2,806 shares on 04/15/2026 and 116 shares on 04/16/2026.
MapLight Therapeutics, Inc. (MPLT) officer Erin Pennock Foff reported a proposed sale of 54,718 common shares, with an aggregate market value of $1,679,842.60 and an approximate sale date of May 4, 2026. The shares were acquired through vested restricted stock units. The notice states sales are to be made pursuant to a previously signed/adopted Rule 10b5-1 selling plan dated December 29, 2025. Recent sales listed were 2,044 shares on April 15 and 1,169 shares on April 16, 2026.
Maplight Therapeutics, Inc. submitted a Form 144 notice listing 52,428 shares of common stock associated with a broker-dealer, Jefferies LLC, and showing an aggregate figure of $1,609,539.60. The filing lists prior sales by James Lillie of 1,730 and 2,783 shares on 04/15/2026 and 04/16/2026, respectively.